Zhu et al. [31] conducted a meta-analysis which demonstrated that elevated lncRNA XIST expression predicted poor OS, poor DFS, larger tumor size, increased distant metastasis and advanced tumor stage, suggesting that high lncRNA XIST expression may serve as a novel biomarker for poor prognosis and metastasis in cancers (CRC, GC, HCC, ESCC, pancreatic cancer [PC], nasopharyngeal carcinoma [NPC], and glioma). This evidence concerns the gene XIST and neoplasm.